{"id":4538,"date":"2020-04-02T11:46:27","date_gmt":"2020-04-02T09:46:27","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=4538"},"modified":"2020-10-07T19:15:20","modified_gmt":"2020-10-07T17:15:20","slug":"dynacure-announces-e50m-55m-series-c-financing","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/dynacure-announces-e50m-55m-series-c-financing\/","title":{"rendered":"Dynacure Announces \u20ac50M ($55M) Series C Financing"},"content":{"rendered":"<h2><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-4206\" src=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\" alt=\"\" width=\"274\" height=\"178\" \/><\/h2>\n<h2><em>-Funding supports ongoing Phase 1 \/2 \u2018Unite-CNM\u2019 study of DYN101 in Patients with <\/em><em>Myotubular and Centronuclear Myopathies<\/em><em>&#8211;<\/em><\/h2>\n<p>STRASBOURG\/PHILADELPHIA, April 2, 2020 \u2013 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a \u20ac50 million Series C financing led by Perceptive Advisors.<\/p>\n<p>New investors participating in this financing include Bpifrance Large Venture and funds managed by Tekla Capital Management LLC. Dynacure\u2019s existing investors Andera Partners, Bpifrance, Kurma Partners and Pontifax also meaningfully participated.\u00a0 In connection with the financing, Henry Skinner, Ph.D., Senior Vice President of Tekla Capital Management, will join the Dynacure board of directors.<\/p>\n<p>\u201cWe are excited to partner with Dynacure as they pioneer the use of antisense therapy for the treatment of Myotubular and Centronuclear Myopathies,\u201d said Ellen Hukkelhoven, Managing Director of Perceptive Advisors.\u00a0 \u201cPerceptive has long been committed to supporting novel approaches in rare diseases and we look forward to working with the dedicated team at Dynacure to bring DYN101 and other medicines to patients faster.\u201d<\/p>\n<p>DYN101 is an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2) for the treatment of Myotubular and Centronuclear Myopathies (CNM).\u00a0\u00a0 Proceeds from the financing will be used to advance Dynacure\u2019s lead program, DYN101, through an ongoing Phase 1\/2 clinical trial in adults, expand the DYN101 clinical program to include treatment of pediatric patients and to continue to grow the company and its pipeline.<\/p>\n<p>\u201cSince the company\u2019s inception in 2016, Dynacure has made significant progress in a very short time, resulting in the first CNM patient dosed with their antisense medicine, DYN101, in March 2020,\u201d said Laurent Higueret, Investment Director at Bpifrance Large Venture. \u201cWe view this financing as our commitment to supporting Dynacure as they advance DYN101 and become one of the industry\u2019s future rare disease leaders.\u201d<\/p>\n<p>\u201cWith the support of our outstanding group of investors, this financing positions us well to advance DYN101 through Phase 1\/2 clinical evaluation in both adult and pediatric patients and expand our pipeline into other rare muscle disorders to strengthen Dynacure\u2019s growth,\u201d said Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure.<\/p>\n<p>CNMs are serious, rare, life-threatening disorders that affect skeletal muscles from birth. Centronuclear Myopathies affect between 4,000 and 5,000 patients in the EU, US, Japan and Australia<sup>1<\/sup>. DYN101 is being developed in collaboration with Ionis Pharmaceuticals, the leader in RNA-targeted drug discovery.\u00a0 Preclinical efficacy observed in multiple mouse models of the disease gives confidence in the ability to demonstrate potential disease-modifying results in humans.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About the Phase 1 \/ 2 Study \u2018Unite-CNM\u2019 (DYN101-C101)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n<p>\u2018Unite-CNM\u2019 (DYN101-C101) study is a multicenter, ascending dose study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DYN101 in approximately 18 patients greater than 16 years of age with X-linked (XLCNM) or autosomal dominant CNM (ADCNM). Enrolled patients will have a run-in period or be rolled over from an ongoing natural history study, sponsored by the Institute of Myology in France, that have XLCNM or ADCNM. The Phase 1 \/ 2 study will primarily focus on finding an optimal dose for DYN101 based on safety and tolerability. After 12 weeks of treatment, multiple domains of efficacy will also be assessed in an exploratory analysis, which include muscular function, respiratory function and muscle strength. After completing the Unite-CNM study, Dynacure plans to initiate a registrational Phase 2 \/ 3 study (all age groups) that would include US and European sites.<\/p>\n<p>&nbsp;<\/p>\n<p>More information can be found at\u00a0<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04033159?term=dynacure&amp;rank=1\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04033159?term=dynacure&amp;rank=1<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About Centronuclear Myopathies<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>Myotubular and Centronuclear Myopathies (CNM) are serious, rare, life-threatening disorders that affect skeletal muscles from birth. CNMs derive their name based on the central location of the muscle fiber nucleus, which is an abnormal finding observed in muscle biopsies. The disease is driven by mutations in multiple genes including MTM1, DNM2, and BIN1. Dynacure scientists have discovered the link between an increase in DNM2 and the direct cause of the disease (Cowling et al 2014 JCI). There are many genetic forms of CNM including X-linked recessive (XLCNM\/ Myotubular Myopathy), autosomal dominant (ADCNM), and autosomal recessive (ARCNM), which are all associated with poor prognosis. Centronuclear Myopathies affect between 4,000 and 5, 000 patients in the EU, US, Japan and Australia<sup>1<\/sup>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About DYN101<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>DYN101, an investigational antisense oligonucleotide using Ionis\u2019 proprietary antisense technology, is designed to modulate the expression of dynamin 2 (DNM2) for the treatment of Myotubular and Centronuclear Myopathies (CNM). Preclinical studies have demonstrated that DYN101 has the potential to be disease modifying in CNM, with compelling preclinical efficacy in treating animal models of XLCNM and ADCNM<sup>2,3<\/sup>. Prevention and reversion of the disease was observed with a clear dose-dependent improvement in whole body strength and mice survival.<\/p>\n<p>&nbsp;<\/p>\n<p>The development plan for DYN101 was designed to be broad and it is the only known program being investigated for most CNM populations, XLCNM and ADCNM. DYN101 has been granted Orphan Drug designations by the US FDA and EMA.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>About<\/strong> <strong>Dynacure<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs.\u00a0 Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Myotubular and Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders. The company maintains its headquarters in Strasbourg, France and a corporate office in Philadelphia, PA, USA.\u00a0 Dynacure\u2019s investors are Andera Partners, Bpifrance\/ Bpifrance Large Venture, IdInvest, Ionis Pharmaceuticals, Kurma Partners, Perceptive Advisors, Pontifax and funds managed by Tekla Capital Management LLC.<\/p>\n<p>&nbsp;<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.dynacure.com\/\">www.dynacure.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>-Funding supports ongoing Phase 1 \/2 \u2018Unite-CNM\u2019 study of DYN101 in Patients with Myotubular and Centronuclear Myopathies&#8211; STRASBOURG\/PHILADELPHIA, April 2, 2020 \u2013 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a \u20ac50 million Series C financing led by Perceptive&#8230;<\/p>\n","protected":false},"author":2,"featured_media":4206,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-4538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"-Funding supports ongoing Phase 1 \/2 \u2018Unite-CNM\u2019 study of DYN101 in Patients with Myotubular and Centronuclear Myopathies&#8211; STRASBOURG\/PHILADELPHIA, April 2, 2020 \u2013 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a \u20ac50 million Series C financing led by Perceptive...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-02T09:46:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-07T17:15:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"274\" \/>\n\t<meta property=\"og:image:height\" content=\"178\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Dynacure Announces \u20ac50M ($55M) Series C Financing\",\"datePublished\":\"2020-04-02T09:46:27+00:00\",\"dateModified\":\"2020-10-07T17:15:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\"},\"wordCount\":954,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\",\"name\":\"Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\",\"datePublished\":\"2020-04-02T09:46:27+00:00\",\"dateModified\":\"2020-10-07T17:15:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg\",\"width\":274,\"height\":178},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dynacure Announces \u20ac50M ($55M) Series C Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/","og_locale":"en_US","og_type":"article","og_title":"Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS","og_description":"-Funding supports ongoing Phase 1 \/2 \u2018Unite-CNM\u2019 study of DYN101 in Patients with Myotubular and Centronuclear Myopathies&#8211; STRASBOURG\/PHILADELPHIA, April 2, 2020 \u2013 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a \u20ac50 million Series C financing led by Perceptive...","og_url":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2020-04-02T09:46:27+00:00","article_modified_time":"2020-10-07T17:15:20+00:00","og_image":[{"width":274,"height":178,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg","type":"image\/jpeg"}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Dynacure Announces \u20ac50M ($55M) Series C Financing","datePublished":"2020-04-02T09:46:27+00:00","dateModified":"2020-10-07T17:15:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/"},"wordCount":954,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/","url":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/","name":"Dynacure Announces \u20ac50M ($55M) Series C Financing - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg","datePublished":"2020-04-02T09:46:27+00:00","dateModified":"2020-10-07T17:15:20+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/07\/Dynacure-2.jpg","width":274,"height":178},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/dynacure-announces-e50m-55m-series-c-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dynacure Announces \u20ac50M ($55M) Series C Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/4538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=4538"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/4538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media\/4206"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=4538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=4538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}